Compare Lattice Semiconductor Corporation Common Stock (LSCC) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lattice Semiconductor Corporation Common Stock vs Spyre Therapeutics Inc. Common Stock — how do they compare? Lattice Semiconductor Corporation Common Stock trades at $113.11 (market cap $17.90B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Lattice Semiconductor Corporation Common Stock is far larger — about 2.4× Spyre Therapeutics Inc. Common Stock's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, Lattice Semiconductor Corporation Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Lattice Semiconductor Corporation Common Stock for 6 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| LSCC | SYRE | |
|---|---|---|
Market Cap | $17.90B | $7.52B |
Volume | 1,042,232 | 1,441,031 |
Sector | Technology | Health |
52-Week High | $155.27 | $108.92 |
52-Week Low | $61.73 | $22.18 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $17.77B | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lattice Semiconductor (LSCC) trades at $121.15, down 1.38% today, with a bullish technical signal from moving averages. The company shows strong revenue growth projections from $523M in 2025 to $651M in 2026, though current valuation metrics remain elevated with a P/E of 504.2. Recent news highlights leadership in AI infrastructure security and new FPGA product launches, supported by overwhelmingly positive analyst sentiment with 88% buy ratings.
LSCC presents growth potential through AI-driven semiconductor demand and expanding product portfolio, but faces risks from high valuations and competitive pressures. The consensus price target of $162.14 suggests 34% upside, though investors should monitor execution on projected margin expansion from 0.58% to 5.57% net profit margin.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Lattice Semiconductor Corporation Common Stock
Lattice Semiconductor develops low-power programmable chips, known as FPGAs. Its products are used in communications, computing, industrial, and automotive applications.
Read more on LSCC →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
